EP4328218A3 - Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat - Google Patents

Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat Download PDF

Info

Publication number
EP4328218A3
EP4328218A3 EP24150976.9A EP24150976A EP4328218A3 EP 4328218 A3 EP4328218 A3 EP 4328218A3 EP 24150976 A EP24150976 A EP 24150976A EP 4328218 A3 EP4328218 A3 EP 4328218A3
Authority
EP
European Patent Office
Prior art keywords
antiviral
pharmaceutical preparation
dihydroquinazoline derivative
dihydroquinazoline
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24150976.9A
Other languages
English (en)
French (fr)
Other versions
EP4328218A2 (de
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Peter Van Hoogevest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIC246 AG and Co KG
Original Assignee
AIC246 AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4328218(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AIC246 AG and Co KG filed Critical AIC246 AG and Co KG
Publication of EP4328218A2 publication Critical patent/EP4328218A2/de
Publication of EP4328218A3 publication Critical patent/EP4328218A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft pharmazeutische Zubereitungen, insbesondere zur intravenösen Verabreichung, die {8-Fluor-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluormethyl)phenyl]-3,4-dihydrochinazolin-4-yl}essigsäure in Kombination mit zumindest einem Hilfsstoff ausgewählt aus den Cyclodextrinen, Lysin und Arginin enthalten, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere ihre Verwendung als antivirales Mittel vorzugsweise gegen Cytomegalieviren.
EP24150976.9A 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat Pending EP4328218A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP19176985.0A EP3556350B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4
EP13707000.9A EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP13707000.9A Division EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
EP19176985.0A Division EP3556350B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4

Publications (2)

Publication Number Publication Date
EP4328218A2 EP4328218A2 (de) 2024-02-28
EP4328218A3 true EP4328218A3 (de) 2024-04-10

Family

ID=47757622

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13707000.9A Active EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
EP19176985.0A Active EP3556350B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4
EP24150976.9A Pending EP4328218A3 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP13707000.9A Active EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
EP19176985.0A Active EP3556350B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4

Country Status (37)

Country Link
US (1) US10603384B2 (de)
EP (3) EP2819648B1 (de)
JP (1) JP6387486B2 (de)
KR (1) KR102149561B1 (de)
CN (2) CN110433166A (de)
AU (1) AU2013224947B2 (de)
BR (1) BR112014020946B1 (de)
CA (1) CA2865203C (de)
CL (1) CL2014002306A1 (de)
CO (1) CO7061076A2 (de)
CY (1) CY1121910T1 (de)
DE (1) DE102012101680A1 (de)
DK (2) DK2819648T3 (de)
EA (1) EA026584B1 (de)
ES (2) ES2972133T3 (de)
FI (1) FI3556350T3 (de)
HR (2) HRP20191369T1 (de)
HU (2) HUE045949T2 (de)
IL (1) IL234363B (de)
IN (1) IN2014MN01892A (de)
LT (2) LT3556350T (de)
MA (1) MA35941B1 (de)
ME (1) ME03448B (de)
MX (1) MX369666B (de)
MY (1) MY172310A (de)
NZ (1) NZ628444A (de)
PH (1) PH12014501937B1 (de)
PL (2) PL2819648T3 (de)
PT (2) PT2819648T (de)
RS (2) RS65137B1 (de)
SG (1) SG11201405294XA (de)
SI (2) SI3556350T1 (de)
SM (2) SMT201900458T1 (de)
TN (1) TN2014000345A1 (de)
UA (1) UA111415C2 (de)
WO (1) WO2013127970A1 (de)
ZA (1) ZA201405949B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
CN120097924A (zh) * 2013-06-19 2025-06-06 Aic246股份两合公司 无定形莱特莫韦及其用于口服施用的固体药物制剂
CN109310346A (zh) 2016-06-03 2019-02-05 阿特里亚创新私人有限公司 用于脉搏特性的检测和可靠获取的设备
PL3592362T3 (pl) * 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
EP3886798B1 (de) 2018-11-29 2026-01-28 Venatorx Pharmaceuticals, Inc. Kombinationszusammensetzungen mit einem beta-lactamase-inhibitor und verwendungen davon
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
PY2116975A (es) 2020-02-27 2022-04-05 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN118574603A (zh) * 2022-02-23 2024-08-30 株式会社Lg化学 包含异𫫇唑啉衍生物的注射制剂及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
WO2024037485A1 (zh) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法
CN119015222B (zh) * 2024-08-28 2025-12-09 石家庄四药有限公司 一种来特莫韦注射液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE69909128T2 (de) * 1998-12-18 2004-05-06 Euphar Group S.R.L. Einschlusskomplexe von dehydroepiandrosteron und korrespondierende pharmazeutische zusammenstellungen
WO2006133822A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen
PT1622880E (pt) * 2003-05-02 2007-06-04 Aicuris Gmbh & Co Kg ''di-hidroquinazolinas substituídas com propriedades antivirais''
US20110019093A1 (en) * 2009-07-24 2011-01-27 Sheng Zhong Method And System For Mitigating Motion Trail Artifacts And Improving Low Contrast Contours In Temporal Filtering Based Noise Reduction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
FR2585705B1 (fr) * 1985-08-05 1989-01-13 Bristol Myers Co Sels de cephalosporine et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
WO2000055153A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
WO2005051922A1 (en) * 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
EP1846410B1 (de) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydrochinazolinone als 5ht-modulatoren

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69909128T2 (de) * 1998-12-18 2004-05-06 Euphar Group S.R.L. Einschlusskomplexe von dehydroepiandrosteron und korrespondierende pharmazeutische zusammenstellungen
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
PT1622880E (pt) * 2003-05-02 2007-06-04 Aicuris Gmbh & Co Kg ''di-hidroquinazolinas substituídas com propriedades antivirais''
WO2006133822A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen
US20110019093A1 (en) * 2009-07-24 2011-01-27 Sheng Zhong Method And System For Mitigating Motion Trail Artifacts And Improving Low Contrast Contours In Temporal Filtering Based Noise Reduction

Also Published As

Publication number Publication date
SMT201900458T1 (it) 2019-11-13
PT2819648T (pt) 2019-09-05
LT3556350T (lt) 2024-02-26
NZ628444A (en) 2016-07-29
CA2865203C (en) 2019-11-05
EA201400963A1 (ru) 2015-02-27
SI3556350T1 (sl) 2024-03-29
HUE065553T2 (hu) 2024-06-28
SMT202400068T1 (it) 2024-03-13
HRP20191369T1 (hr) 2019-11-01
ME03448B (de) 2020-01-20
EP2819648B1 (de) 2019-05-29
HRP20240197T1 (hr) 2024-04-26
RS59157B1 (sr) 2019-10-31
CN110433166A (zh) 2019-11-12
PL2819648T3 (pl) 2019-10-31
AU2013224947B2 (en) 2017-06-29
ZA201405949B (en) 2021-07-28
ES2972133T3 (es) 2024-06-11
AU2013224947A1 (en) 2014-09-18
SG11201405294XA (en) 2014-11-27
BR112014020946B1 (pt) 2022-04-05
EP4328218A2 (de) 2024-02-28
SI2819648T1 (sl) 2019-10-30
WO2013127970A1 (de) 2013-09-06
MX2014010364A (es) 2014-12-05
EP3556350B1 (de) 2024-01-10
KR102149561B1 (ko) 2020-08-31
PT3556350T (pt) 2024-02-15
US10603384B2 (en) 2020-03-31
LT2819648T (lt) 2019-09-10
UA111415C2 (uk) 2016-04-25
PH12014501937A1 (en) 2014-11-24
TN2014000345A1 (en) 2015-12-21
MX369666B (es) 2019-11-14
HUE045949T2 (hu) 2020-01-28
MA35941B1 (fr) 2014-12-01
PH12014501937B1 (en) 2022-07-15
CY1121910T1 (el) 2020-10-14
DK3556350T3 (da) 2024-02-12
EP2819648A1 (de) 2015-01-07
BR112014020946A2 (de) 2017-06-20
PL3556350T3 (pl) 2024-05-06
IL234363B (en) 2020-04-30
ES2741698T3 (es) 2020-02-12
DE102012101680A1 (de) 2013-08-29
CO7061076A2 (es) 2014-09-19
JP6387486B2 (ja) 2018-09-12
DK2819648T3 (da) 2019-08-26
US20150133461A1 (en) 2015-05-14
IN2014MN01892A (de) 2015-07-10
CL2014002306A1 (es) 2014-11-28
CN104144678A (zh) 2014-11-12
MY172310A (en) 2019-11-21
FI3556350T3 (fi) 2024-02-14
JP2015508801A (ja) 2015-03-23
RS65137B1 (sr) 2024-02-29
CA2865203A1 (en) 2013-09-06
EP3556350A1 (de) 2019-10-23
EA026584B1 (ru) 2017-04-28
HK1205462A1 (en) 2015-12-18
KR20140130683A (ko) 2014-11-11

Similar Documents

Publication Publication Date Title
UA111415C2 (uk) Фармацевтичний препарат, що містить похідну дигідрохіназоліну з противірусною активністю
HK1204770A1 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2016065226A8 (en) Indole carboxamides compounds useful as kinase inhibitors
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
EP4279128A3 (de) Neuartige antikörper mit bindung an tfpi und zusammensetzung damit
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2014005895A (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
GEAP202115141A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
BR112014027213A2 (pt) nova composição de alfentanil para o tratamento da dor aguda
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
MX382507B (es) Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.
WO2011066201A3 (en) Methods and systems for treating and preventing cardiac injury in dystrophic subjects
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
WO2014172453A3 (en) Novel compositions useful in treating brain-related diseases or disorders and methods using same
HK1205511A1 (zh) 二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐及它们作为抗病毒剂的用途
DE602006009511D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen
DE112008001612A5 (de) Antimikrobiell wirkende kosmetische und/oder pharmazeutische Zusammensetzungen zur topischen Anwendung, Verfahren zu deren Herstellung und ihre Anwendung in der Behandlung von Krankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2819648

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3556350

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0239840000

Ipc: A61K0009080000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 239/84 20060101ALI20240301BHEP

Ipc: A61P 31/22 20060101ALI20240301BHEP

Ipc: A61P 31/12 20060101ALI20240301BHEP

Ipc: A61K 31/517 20060101ALI20240301BHEP

Ipc: C07D 417/12 20060101ALI20240301BHEP

Ipc: A61K 31/00 20060101ALI20240301BHEP

Ipc: A61K 9/00 20060101ALI20240301BHEP

Ipc: A61K 47/40 20060101ALI20240301BHEP

Ipc: A61K 47/18 20170101ALI20240301BHEP

Ipc: A61K 9/08 20060101AFI20240301BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107621

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241223

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20260326